Related Experiment Video

Updated: Mar 31, 2026

Author Spotlight: Repetitive Transcranial Magnetic Stimulation Combined with Movement Observation in Cerebral Palsy
07:20

Author Spotlight: Repetitive Transcranial Magnetic Stimulation Combined with Movement Observation in Cerebral Palsy

Published on: August 9, 2024

2.1K

Safety of Botulinum Toxin Type A for Children With Nonambulatory Cerebral Palsy

Priya Edwards1, Leanne Sakzewski2, Lisa Copeland3

  • 1Queensland Paediatric Rehabilitation Service, Lady Cilento Children's Hospital, Brisbane Australia; Queensland Cerebral Palsy and Rehabilitation Research Centre, School of Medicine, The University of Queensland, priya.edwards@health.qld.gov.au.

Pediatrics
|October 21, 2015
PubMed

Insights

Intramuscular botulinum toxin A injections are safe for nonambulatory children with cerebral palsy (CP), showing no increased risk of moderate/serious adverse events compared to sham procedures. Multiple injections did not elevate safety concerns.

Area of Science:

  • Pediatric Rehabilitation
  • Neurology
  • Pharmacology

Background:

  • Cerebral palsy (CP) often causes spasticity in nonambulatory children, impacting care and comfort.
  • Botulinum toxin A (BoNT-A) is used to manage spasticity, but its safety in this population requires rigorous evaluation.

Purpose of the Study:

  • To assess the safety of intramuscular botulinum toxin A (BoNT-A) injections for managing spasticity in nonambulatory children with cerebral palsy (CP).
  • To compare adverse event rates between BoNT-A and sham procedures in children with CP.

Main Methods:

  • A randomized controlled trial involving nonambulatory children with CP.
  • Participants received either BoNT-A or a sham procedure in Cycle 1, with crossover in Cycle 2.
  • Adverse events were graded for severity and causality by a masked pediatric rehabilitation specialist.

Main Results:

  • No significant difference in moderate/serious adverse events (AEs) between BoNT-A and sham groups in Cycle 1 (p = .64) or Cycle 2 (p = .47).
  • In Cycle 2, some mild AEs were related to BoNT-A, with 1 serious and 3 moderate AEs also noted.
  • The incidence rate ratio for moderate/serious AEs did not differ significantly between groups.

Conclusions:

  • Intramuscular BoNT-A injections are safe for nonambulatory children with CP, with no greater risk of moderate/serious AEs than sham procedures.
  • Repeated BoNT-A injections (up to two episodes) did not increase the risk of moderate/serious adverse events.
Abstract

More Related Videos

Isolation and Quantification of Botulinum Neurotoxin From Complex Matrices Using the BoTest Matrix Assays12:25

Isolation and Quantification of Botulinum Neurotoxin From Complex Matrices Using the BoTest Matrix Assays

Published on: March 3, 2014

16.7K
Author Spotlight: Exploring the Potential of Massage Therapy in Cerebral Palsy Using Animal Models08:24

Author Spotlight: Exploring the Potential of Massage Therapy in Cerebral Palsy Using Animal Models

Published on: August 11, 2023

2.8K

Related Concept Videos

Directly Acting Muscle Relaxants: Dantrolene and Botulinum Toxin01:26

Directly Acting Muscle Relaxants: Dantrolene and Botulinum Toxin

Directly acting muscle relaxants like dantrolene and botulinum toxin (BoNT) have distinct mechanisms and applications. Dantrolene, a hydantoin derivative, acts on the ryanodine receptor (RYR1) in skeletal muscle cells. RYR1 are calcium channels present at the sarcoplasmic reticulum membrane. In response to excitation, they release calcium ions from the sarcoplasmic reticulum to the cytosol. Calcium promotes actin-myosin-mediated contraction of muscles.
The binding of dantrolene to the RYR1...
1.4K
Skeletal Muscle Relaxants: Therapeutic Uses01:31

Skeletal Muscle Relaxants: Therapeutic Uses

Skeletal muscle relaxants are used to relax muscle tone and alleviate painful muscle contractions. However, the choice of skeletal muscle relaxants depends on the duration of the surgical procedure in order to minimize potential side effects. Skeletal muscle relaxants like neuromuscular blocking agents [NMBAs] are commonly employed as adjuvants alongside general anesthetics in clinical settings. NMBAs are also used to maintain controlled ventilation during surgery of the larynx or pharynx...
1.2K
Skeletal Muscle Relaxants: Adverse Effects01:21

Skeletal Muscle Relaxants: Adverse Effects

Skeletal muscle relaxants are widely used for muscle paralysis and relieving pain following any muscle injury or stiffness. However, depending on the drug type, they can have adverse effects that range from mild to severe. Usually, nondepolarizing neuromuscular blockers have minimal side effects. For example, drugs like d-tubocurarine, cisatracurium, and rocuronium cause hypotension, whereas drugs like baclofen, when stopped abruptly, can lead to the recurrence of spastic conditions.
Unlike...
1.1K
Depolarizing Blockers: Pharmocokinetics01:19

Depolarizing Blockers: Pharmocokinetics

Depolarizing blockers are administered through intravenous injection. Succinylcholine is the most common choice of depolarizing blockers in emergency clinical practices. Although they have a rapid onset, they readily diffuse away from the motor end plate into the extracellular fluid. They are metabolized by enzymes such as liver butyrylcholinesterase and plasma pseudocholinesterases. This produces a short duration of action, typically 5-10 minutes long, unlike nondepolarizing blockers, which...
720